Eli Lilly and Company has confirmed it will announce its third-quarter 2025 financial results on Thursday, October 30, 2025. The company will also hold a conference call for the investment community and media on the same day at 10 a.m. Eastern time to provide further details on its financial performance. This announcement follows a series of significant clinical trial updates. On October 17, 2025, Lilly announced positive results from the primary overall survival analysis of the Phase 3 monarchE trial for Verzenio in early breast cancer. Additionally, on October 15, 2025, the company reported positive topline results from two Phase 3 trials of orforglipron for type 2 diabetes. These developments, particularly for the company's oncology and diabetes pipelines, will likely be a key focus during the upcoming earnings call.